Format

Send to:

Choose Destination
See comment in PubMed Commons below
Vaccine. 2008 Feb 20;26(8):1118-27. doi: 10.1016/j.vaccine.2007.11.070. Epub 2007 Dec 17.

The cost-utility of rotavirus vaccination with Rotarix (RIX4414) in the Netherlands.

Author information

  • 1Institute for Medical Technology Assessment, Erasmus University Medical Center, Rotterdam, The Netherlands. l.goossens@erasmusmc.nl

Abstract

The objective of this study was to estimate the cost-utility of mass vaccination of 0-4-year-old children with Rotarix in the Netherlands. We used a Markov process with Dutch data on incidence, resource use and costs (GP, hospitalisation, productivity loss and household costs) to compare vaccination to conventional treatment from a societal perspective. Utility loss due to rotavirus-induced diarrhoea was measured using EQ5D, with GPs and paediatricians serving as proxies to fill out the questions. As the costs of a vaccination course ranged from 90 euro to 100 euro per child, the cost-utility ratio varied from 21,900 euro to 35,076 euro per QALY gained. Based on the current study, it is clear that mass vaccination with Rotarix against rotavirus gastroenteritis can be attractive, from an economic and a health care perspective.

PMID:
18215445
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk